Forging a New Future
Mallinckrodt and Endo are joining forces to deliver hope to the patients we serve.
Two legacy companies.
One ambitious path forward.
Mallinckrodt and Endo are preparing to combine and create a global, scaled, diversified therapeutics leader. The new company will include a branded specialty pharmaceuticals business, along with a generics and sterile injectables business, which is intended to be spun off under the name Par Health. The planned merger represents a unique opportunity to align both value and vision for the ultimate benefit of the patients who rely on us. Check back here in the weeks ahead for updates on all that we are starting to create together.
Mallinckrodt-Endo Planned Leadership Team
Recruiting efforts are underway for the Chief Financial Officer and leaders of Business Development & Strategy and Research & Development.
Par Health Planned Leadership Team
Par Health will operate as a segment of the merged company until the generics and sterile injectables business spin-off, which is expected to occur at a later date. Stephen Welch will then become President and CEO of the new standalone company.
Stephen Welch
President & Chief Executive Officer
Jack Boyle
Chief Financial Officer
Andrew Gonce
Chief Operations Officer
Jason Goodson
Chief Strategy Officer
Kass Harrold
Chief Administration Officer
Jake Longenecker
Matthew J. Maletta
Mick McGuinness
Global Head of Quality and Compliance
Scott Sims
Chief Commercial Officer and Business Operations, Injectable Solutions and Generics
Jeffrey Wiegers
Chief Transformation Officer